NorthWest Biotherapeutics Inc (NWBO)

[j e d]

again it seems like you’re just throwing these words together without understanding what you’re talking about. gibberish. it’s okay, this is complex stuff, but you’re diving into an area you seem to know nothing about and making weird nonsense claims. it’s hard to refute what you’ve said because what you said isn’t even coherent. the original OS comparison between ITT and placebo was confounded by crossover. the new OS comparison to an ECA fixed this. NWBO admits the original OS endpoint was confounded, which is why they changed to using an ECA. nowhere does NWBO state their new OS endpoint is confounded, that doesn’t even make sense.